Royalty Pharma
RPRX
RPRX
376 hedge funds and large institutions have $9.22B invested in Royalty Pharma in 2024 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 160 increasing their positions, 113 reducing their positions, and 48 closing their positions.
Holders
376
Holders Change
+14
Holders Change %
+3.87%
% of All Funds
5.45%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.1%
New
64
Increased
160
Reduced
113
Closed
48
Calls
$15.3M
Puts
$10.7M
Net Calls
+$4.62M
Net Calls Change
-$3.44M
Top Buyers
Top Sellers
| 1 |
1
Morgan Stanley
New York
|
$1.34B |
| 2 |
2
Swedbank
Stockholm,
Sweden
|
$0 |
| 3 |
3
Man Group
London,
United Kingdom
|
$5.99M |
| 4 |
4
Goldman Sachs
New York
|
$18.3M |
| 5 |
SCM
5
Suvretta Capital Management
New York
|
$68.3M |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
426
Group One Trading
Chicago,
Illinois
| – | – | – | – |
|
|
PCM
427
Penserra Capital Management
Orinda,
California
| $0 | 27 | – | – |
|
428
Parallax Volatility Advisers
San Francisco,
California
| – | – | – | – |
|